Last reviewed · How we verify

Helicobacter pylori eradication — Competitive Intelligence Brief

Helicobacter pylori eradication (Helicobacter pylori eradication) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination therapy / Proton pump inhibitor-based regimen. Area: Gastroenterology / Oncology (cancer prevention).

marketed Antibiotic combination therapy / Proton pump inhibitor-based regimen Gastroenterology / Oncology (cancer prevention) Small molecule Live · refreshed every 30 min

Target snapshot

Helicobacter pylori eradication (Helicobacter pylori eradication) — National Cancer Center, Korea. Helicobacter pylori eradication involves the use of antibiotic-based combination therapy to eliminate the bacterium from the gastric mucosa.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Helicobacter pylori eradication TARGET Helicobacter pylori eradication National Cancer Center, Korea marketed Antibiotic combination therapy / Proton pump inhibitor-based regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination therapy / Proton pump inhibitor-based regimen class)

  1. National Cancer Center, Korea · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Helicobacter pylori eradication — Competitive Intelligence Brief. https://druglandscape.com/ci/helicobacter-pylori-eradication. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: